CAS 1309444-75-4

K145

CAS : 1309444-75-4

K145 is a small molecule drug that inhibits the activity of bortezomib, an inhibitor of sphingosine kinase (SPK). K145 has been shown to have hypoglycemic effects in mice, and may be useful for treatment of diabetes. K145 also has anti-inflammatory properties that are mediated through its inhibition of toll-like receptor (TLR) 4 signaling. K145 was found to inhibit colony-stimulating factor (CSF) production by macrophages and downregulate the expression of CSF receptors in the cell membrane. K145 may also be useful in cancer therapy due to its ability to inhibit tumor growth by inhibiting CSF production.

Formule : C₁₈H₂₄N₂O₃S

Degré de pureté : Min. 95%

Masse moléculaire : 348.5 g/mol

Ref: 3D-JCC44475

K145

CAS : 1309444-75-4

K145: Selective, oral SphK2 inhibitor, IC50 4.3 μM, Ki 6.4 μM, promotes cell apoptosis, strong antitumor effect, inactive against SphK1/other kinases.

Formule : C₁₈H₂₄N₂O₃S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 348.46

Ref: TM-T11739